#gilead

Gilead Q1 EPS $2.03 beats; raised guidance overshadowed by $11.5bn deal charge

Gilead Sciences beat on EPS and revenue and raised 2026 product-sales guidance, but a $11.5 billion in-process R&D charge tied to three pending acquisitions sent shares down 1.6 per cent and flipped reported EPS guidance into a loss range.